http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Seagen (SGEN) and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV in Advanced UC
-
Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
-
Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer
-
Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
-
Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cance
-
FDA Approves VESIcare LS™ (solifenacin succinate) Oral Suspension for Pediatric Patients
-
CytomX Therapeutics (CTMX), Astellas Enter Collaboration to Develop Probody T-Cell
-
CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer
-
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
-
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for PADCEV™ (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
-
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
-
Seattle Genetics (SGEN) and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV for Advanced Bladder Cancer
-
Seattle Genetics and Astellas Announce Updated Results from Phase 1b/2 Trial of PADCEV™ (enfortumab vedotin-ejfv) in Combination with Immune Therapy Pembrolizumab as Investigational First-Line Treat
-
FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' (SGEN) PADCEV for People with Locally Advanced or Metastatic Urothelial Cancer
-
FDA Grants Accelerated Approval to Astellas' and Seattle Genetics' PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bladder
-
FDA Grants Accelerated Approval to Astellas’ and Seattle Genetics’ PADCEV™ (enfortumab vedotin-ejfv) for People with Locally Advanced or Metastatic Urothelial Cancer, the Most Common Type of Bla
-
Seattle Genetics (SGEN), Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA in Patients with Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
-
Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merck to Evaluate Enfortumab Vedotin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Urothelial Canc
-
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Blad
-
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Announce U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application in Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics (SGEN), Astellas Announce Submission of BLA to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Seattle Genetics Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Announce Submission of Biologics License Application to FDA for Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Astellas Appoints Chelsea Glinski as National Vice President Oncology Sales
-
Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
-
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Announce Positive Topline Results from Pivotal Trial of Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics (SGEN), Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
-
Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program
-
Seattle Genetics and Astellas Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-
Astellas and Seattle Genetics Present at ASCO 2018 on Enfortumab Vedotin in Patients with Locally Advanced or Metastatic Urothelial Cancer Previously Treated with Checkpoint Inhibitor Therapy
-
Seattle Genetics and Astellas Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Seattle Genetics Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
-
Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan
-
GUINNESS WORLD RECORDS™ Title Achieved for Organ Donor Registrations
-
Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine X
-
Astellas Oncology Selects Five C3 Prize™ Finalists to Pitch Ideas for Changing Cancer Care to Panel Including Robert Herjavec at Stanford Medicine X
-
Astellas Oncology Announces Data to be Presented at 2016 ASCO Annual Meeting
-
Astellas Oncology C3 Prize™ to Bring Bright Ideas in Cancer Care to Life with $100,000 in Grants
-
Astellas Names James Robinson President, Americas Operations
-
Astellas and Medivation (MDVN) Announces STRIVE Trial Results Published in Journal of Clinical Oncology
-
Journal of Clinical Oncology Publishes Results From the STRIVE Trial of Enzalutamide Compared to Bicalutamide in Castration-Resistant Prostate Cancer
-
Journal of Clinical Oncology Publishes Results from the STRIVE trial of enzalutamide Compared to bicalutamide in Castration-resistant Prostate Cancer
-
Lancet Oncology Publishes Results From the Phase 2 TERRAIN Trial of Enzalutamide Compared to Bicalutamide in Metastatic Castration-Resistant Prostate Cancer
